Role of STAT3 (signal transducer and activator of transcription 3) activation and its regulation by PTPRT (protein receptor tyrosine phosphatase type T) and response to paclitaxel and cetuximab in patients (P) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Autor: Cirauqui, BC, Peguera, AB, Pi-Sunyer, AQ, Serrano, JLR, Vinolas, MD, Garcia, IT, Garcia, VQ, Vila, MM, Chaib, I, Riera, LC, Diez, AF, Salarich, AP, Company, LA, Fernandez, SE, Peinado, GB, Rubio, CL, Guisasola, CP, Cardus, AM, Costa, RR, Nin, RM

Publikováno v: Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::7f1b0fabff95069307b045e016b88a84
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3378

Surveillance behavior of women with a reported family history of colorectal cancer

Autor: H. Goulard, R. Joseph, Françoise Clavel-Chapelon

Publikováno v: Preventive Medicine / Preventative Medicine
Preventive Medicine / Preventative Medicine, 1999, 28 (2), pp.174-8. ⟨10.1006/pmed.1998.0397⟩

Study objective.The present study tested whether the surveillance behavior of women with a family history of colorectal cancer (CRC) differed from that of women without such a history. Design.The study included 72,710 subjects from the population of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55fd712d934aca9bacd434d6f8056ea
https://www.hal.inserm.fr/inserm-00174534/document

A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates.

Autor: Ma L; Synthorx, Inc., A Sanofi Company, La Jolla, California., Acuff NV; Synthorx, Inc., A Sanofi Company, La Jolla, California., Joseph IB; Synthorx, Inc., A Sanofi Company, La Jolla, California., Ptacin JL; Synthorx, Inc., A Sanofi Company, La Jolla, California., Caffaro CE; Synthorx, Inc., A Sanofi Company, La Jolla, California., San Jose KM; Synthorx, Inc., A Sanofi Company, La Jolla, California., Aerni HR; Synthorx, Inc., A Sanofi Company, La Jolla, California., Carrio R; Sanofi, Orlando, Florida., Byers AM; Sanofi, Orlando, Florida., Herman RW; Synthorx, Inc., A Sanofi Company, La Jolla, California., Pavlova Y; Synthorx, Inc., A Sanofi Company, La Jolla, California., Pena MJ; Synthorx, Inc., A Sanofi Company, La Jolla, California., Chen DB; Synthorx, Inc., A Sanofi Company, La Jolla, California., Buetz C; Synthorx, Inc., A Sanofi Company, La Jolla, California., Ismaili TK; Synthorx, Inc., A Sanofi Company, La Jolla, California., Pham HV; Synthorx, Inc., A Sanofi Company, La Jolla, California., Cucchetti M; Sanofi, Vitry-sur-Seine, France., Sassoon I; Sanofi, Vitry-sur-Seine, France., Koriazova LK; Synthorx, Inc., A Sanofi Company, La Jolla, California., Leveque JA; Synthorx, Inc., A Sanofi Company, La Jolla, California., Shawver LK; Synthorx, Inc., A Sanofi Company, La Jolla, California., Mooney JM; Synthorx, Inc., A Sanofi Company, La Jolla, California., Milla ME; Synthorx, Inc., A Sanofi Company, La Jolla, California.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Oct 01; Vol. 4 (10), pp. 2799-2814.

Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.

Autor: Eisner JR; GeneCentric Therapeutics, Inc., Durham, North Carolina., Beebe KD; GeneCentric Therapeutics, Inc., Durham, North Carolina., Mayhew GM; GeneCentric Therapeutics, Inc., Durham, North Carolina., Shibata Y; GeneCentric Therapeutics, Inc., Durham, North Carolina., Guo Y; GeneCentric Therapeutics, Inc., Durham, North Carolina., Farhangfar C; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Farhangfar F; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Uronis JM; GeneCentric Therapeutics, Inc., Durham, North Carolina., Mooney J; Synthorx, Inc - A Sanofi Company, La Jolla, California., Milburn MV; GeneCentric Therapeutics, Inc., Durham, North Carolina., Foureau D; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., White RL; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Amin A; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Milla ME; Synthorx, Inc - A Sanofi Company, La Jolla, California.

Publikováno v: Cancer research communications [Cancer Res Commun] 2022 Aug 30; Vol. 2 (8), pp. 894-903. Date of Electronic Publication: 2022 Aug 30 (Print Publication: 2022).

Advice on assistance and protection provided by the Scientific Advisory Board of the Organisation for the Prohibition of Chemical Weapons: Part 3. On medical care and treatment of injuries from sulfur mustard.

Autor: Timperley CM; Chair of the OPCW SAB from 2015-2018, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire, United Kingdom. Electronic address: cmtimperley@dstl.gov.uk., Forman JE; Science Policy Adviser and Secretary to the SAB, OPCW, The Hague, 2417, JR, the Netherlands, from 2015-2018., Abdollahi M; Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), and Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran., Al-Amri AS; Saudi Basic Industries Corporation (SABIC), Riyadh, Saudi Arabia., Baulig A; Secrétariat Général de la Défense et de la Sécurité Nationale (SGDSN), Paris, France., Benachour D; LMPMP, Faculty of Technology, Ferhat Abbas University, Setif-1, Algeria., Borrett V; La Trobe Institute for Agriculture and Food, La Trobe University, Victoria, 3086, Australia., Cariño FA; University of the Philippines, Quezon City, Philippines., Curty C; Spiez Laboratory, Spiez, Switzerland., Geist M; BASF SE, Ludwigshafen, Germany., Gonzalez D; Facultad De Química, Universidad de la República, Montevideo, Uruguay., Kane W; Consultant to Monsanto Company, LA, USA., Kovarik Z; Institute for Medical Research and Occupational Health, Zagreb, Croatia., Martínez-Álvarez R; Complutense University, Madrid, Spain., Mourão NMF; Brazilian Chemical Industry, São Paulo, Brazil., Neffe S; Military University of Technology, Warsaw, Poland., Raza SK; Chairperson Accreditation Committee, National Accreditation Board for Testing and Calibration Laboratories (NABL), India., Rubaylo V; State Scientific Research Institute of Organic Chemistry and Technology (GosNIIOKhT), Moscow, Russian Federation., Suárez AG; Universidad Nacional de Rosario, Consejo Nacional de Investigaciones Científicas y Técnicas, Rosario, Argentina., Takeuchi K; National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan., Tang C; Office for the Disposal of Japanese Abandoned Chemical Weapons, Ministry of National Defence, Beijing, China., Trifirò F; Department of Industrial Chemistry, University of Bologna, Bologna, Italy., van Straten FM; Independent Former OPCW SAB Member, South Africa., Vanninen PS; VERIFIN, Department of Chemistry, Faculty of Science, University of Helsinki, Helsinki, Finland., Vučinić S; National Poison Control Centre, Military Medical Academy, Belgrade, Serbia., Zaitsev V; Pontifical Catholic University of Rio de Janeiro, Brazil., Zafar-Uz-Zaman M; National Engineering and Scientific Commission (NESCOM), Islamabad, Pakistan., Zina MS; Faculty of Sciences of Tunis (FST), Tunis, Tunisia., Holen S; Head of Strategy and Policy at the OPCW from 2009 to 2015., Alwan WS; Medicinal Chemistry Department, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Victoria, Australia., Suri V; Intern in the OPCW Office of Strategy and Policy, Summer 2018., Hotchkiss PJ; Senior Science Policy Officer and Secretary to the SAB, OPCW, The Hague, 2417, JR, the Netherlands. Electronic address: peter.hotchkiss@opcw.org., Ghanei M; Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Islamic Republic of Iran.

Publikováno v: Toxicology [Toxicology] 2021 Nov; Vol. 463, pp. 152967. Date of Electronic Publication: 2021 Oct 04.